GET DAILY SIGNALSGlobe Life (GL) Q3 2026 Earnings: Core Stability Tested by Health Segment Pressure
Key Takeaways
- Globe Life reported net income of $361.1 million, or $4.62 per diluted share, down from $4.73 per share in the prior-year quarter.
- Net operating income was $4.84 per diluted share, narrowly above the $4.81 recorded a year earlier but below consensus expectations.
- Total revenue rose 5.2% year over year to $1.60 billion, slightly under analyst estimates of $1.61 billion.
- A swing to an underwriting loss at the United American health unit, driven by high-severity claims and a Medicare claims processing delay, pressured results.
- Full-year 2026 net operating income guidance was trimmed, while the company introduced 2027 guidance and raised its share buyback target.
Why This Quarter Matters
Globe Life Inc. (GL) is a Texas-based insurance holding company offering life insurance, supplemental health insurance, and annuities through several distribution channels. Its third-quarter 2026 results matter because the company has built a reputation for steady, predictable underwriting and strong capital returns. Investors watch this report closely for signs of deterioration in claims trends, which can signal pricing or underwriting stress across the insurance industry. The quarter tested that narrative, as a sharp reversal in one health segment overshadowed otherwise stable results and prompted management to recalibrate its full-year outlook, making the report a key read on the durability of Globe Life's core earnings power. To put the numbers in broader context, I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
The Numbers in Detail
For the third quarter ended September 30, 2026, Globe Life reported net income of $361.1 million, or $4.62 per diluted share, down from $387.8 million, or $4.73 per share, in the year-ago quarter. Net operating income, a non-GAAP metric the company uses to reflect underlying performance, was $378.8 million, or $4.84 per diluted share, compared with $394.2 million, or $4.81 per share, a year earlier.
Total revenue increased 5.2% year over year to $1.60 billion, slightly below the consensus estimate of $1.61 billion. Net premiums earned rose 6.5% to $1.31 billion, roughly in line with expectations. GAAP earnings per share of $4.62 and operating earnings of $4.84 per share both came in below consensus forecasts, which stood near $4.85 to $4.89 per share.
The primary drag was the United American health segment, which swung from a $16.1 million underwriting gain a year ago to a $6.4 million underwriting loss. Management attributed the reversal to high-severity claims at Evry, a developing group health business, and a claims processing delay at the Centers for Medicare and Medicaid Services (CMS) that pushed roughly $7 million of excess Medicare Supplement claims into the quarter. Partially offsetting this, net investment income rose 3%, and the fixed maturity portfolio earned a taxable equivalent effective yield of 5.33%, up from 5.26% a year earlier.
Market Reaction
Globe Life shares traded down roughly 6.5% to about $158.50 immediately after the results, reflecting investor disappointment that both earnings per share and revenue landed below consensus estimates. The market's focus centered on the underwriting loss at United American and the guidance reduction that followed, even though management characterized the pressures as isolated rather than systemic. The raised buyback target and the introduction of 2027 guidance signaled management's confidence, but the negative reaction suggests investors weighed the near-term earnings shortfall and the segment-level claims volatility more heavily than the longer-term capital return story.
Forward Outlook and What to Watch
Globe Life adjusted its full-year 2026 net operating income guidance to a range of $15.35 to $15.65 per share, citing the two items affecting the United American General Agency division. Importantly, management framed these as discrete events rather than a change in the underlying core business, and introduced 2027 net operating income guidance of $16.10 to $17.10 per share, representing roughly 7.1% growth at the midpoint.
Investors will want to watch whether the high-severity claims at Evry persist or normalize as that group health business scales, and whether the Medicare Supplement claims timing issue fully resolves in the fourth quarter. Underwriting margin trends, excluding assumption updates, will also be a key indicator of pricing discipline.
On the capital front, the company repurchased 1.1 million shares for $185 million during the quarter and raised its full-year 2026 buyback outlook to between $725 million and $775 million. Sustained investment income growth, the yield on the fixed maturity portfolio, and the pace of share repurchases will all remain important factors for shareholders monitoring the company's path toward its 2027 targets.
One Tool That Helps with Earnings Analysis
One tool I’ve found useful for digging into post-earnings moves and comparing peers is Tickeron’s AI Screener. It lets me filter equities by industry, performance metrics, and technical signals to quickly surface relevant ideas and put recent developments into broader context. I typically spend just a few minutes running a screen after reports like this one.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
GL's MACD Histogram just turned positive
The Moving Average Convergence Divergence (MACD) for GL turned positive on October 12, 2026. Looking at past instances where GL's MACD turned positive, the stock continued to rise in 27 of 46 cases over the following month. The odds of a continued upward trend are 59%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where GL's RSI Indicator exited the oversold zone, 7 of 15 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 47%.
The Momentum Indicator moved above the 0 level on October 13, 2026. You may want to consider a long position or call options on GL as a result. In 60 of 105 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 57%.
Following a +0.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where GL advanced for three days, in 217 of 380 cases, the price rose further within the following month. The odds of a continued upward trend are 57%.
Bearish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 38%.
GL broke above its upper Bollinger Band on October 20, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GL entered a downward trend on October 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 36 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 43 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 60, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 48 (best 1 - 100 worst), indicating steady price growth. GL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 69 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.119) is normal, around the industry mean (1.338). P/E Ratio (11.093) is within average values for comparable stocks, (19.749). GL's Projected Growth (PEG Ratio) (1.360) is slightly higher than the industry average of (0.463). Dividend Yield (0.008) settles around the average of (0.046) among similar stocks. P/S Ratio (2.251) is also within normal values, averaging (1.303).
The Tickeron SMR rating for this company is 85 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a holding company, which engages in the provision of individual life and supplemental health insurance products and services
Industry LifeHealthInsurance
Advertisement